Abionyx Pharma

ABNX

Company Profile

  • Business description

    Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

  • Contact

    33-43 Avenue Georges Pompidou-Bat D2
    Balma31130
    FRA

    T: +33 562249706

    https://www.abionyx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    51

Stocks News & Analysis

stocks

Microsoft earnings: Strong, including Azure, but overall guidance is in line

We think Microsoft stock is moderately undervalued.
stocks

After earnings, is Tesla stock a buy, a sell, or fairly valued?

Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
stocks

3 cheap fully franked stocks

Well priced Aussie shares that offer a tax rebate.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,178.0028.70-0.31%
CAC 408,121.0779.81-0.97%
DAX 4023,958.30160.59-0.67%
Dow JONES (US)47,562.8740.750.09%
FTSE 1009,717.2542.81-0.44%
HKSE25,906.65376.04-1.43%
NASDAQ23,724.96143.810.61%
Nikkei 22552,411.341,085.732.12%
NZX 50 Index13,548.3289.030.66%
S&P 5006,840.2017.860.26%
S&P/ASX 2008,881.9031.30-0.35%
SSE Composite Index3,954.7932.11-0.81%

Market Movers